Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging

As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.

Four Myths About Embedded CMOs, Busted

Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).

How Molecular Biology Technologies Are Transforming Discovery and Development

Advances in PCR, sequencing, automation, and molecular analysis are helping biopharma teams accelerate discovery, improve data quality, and reduce development risk. Thermo Fisher Scientific’s Dr. Anjali Shah discusses how integrated molecular biology workflows are evolving to support increasingly complex therapeutic modalities.

SPECTROSCOPY - High-Precision Tunable Laser Spectroscopy: A “Library-Based” Approach to Quantitative Bioprocess Analytics

The accuracy and speed of analytical measurements play a critical role in biopharmaceutical development and manufacturing. In particular, the ability to quantify both active pharmaceutical ingredients (APIs) and formulation excipients – such as buffers, amino acids, sugars, and surfactants – is essential for ensuring product quality, process consistency, and regulatory compliance.

COLD CHAIN SUSTAINABILITY - Cold Front: The Growing Need for Controlling Cold Storage Energy Costs

The pharmaceutical and biotech industries are not only one of the most prominent users of cold storage solutions today but are also one of the market’s most important growth drivers. Several factors, including the rise of temperature sensitive drugs, growing energy prices, and increasing regulatory scrutiny are inevitably compelling the pharmaceutical industry to consider its use of the global cold chain with sustainability in mind.

Monoclonal vs Polyclonal Antibody Production – Explained Step by Step

Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.

According to Grand View Research, the global therapeutic antibody market will surpass US $2.21 billion by 2030.

Based on our expertise in monoclonal antibody production, let’s take a look at how each antibody type is produced, contrasts their timelines, costs, and use-cases, and ends with clear next steps to keep your project moving.

Improving bioavailability using predictive modeling for solubility enhancement

In this case study, predictive modeling with the OSDPredict™ platform was used to prioritize optimal formulation strategies for a program facing low-solubility challenges. This approach improved exposure and supported accelerated advancement toward Phase I clinical trials.

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

The pharmaceutical industry has spent decades refining drug discovery, biologics manufacturing and fill-finish operations. However, for many combination products today, the greatest risk to launch timelines no longer sits upstream in formulation or production.

BullFrog AI: Applying an End-to-end AI Workflow to Improve Clinical Development 

BullFrog AI Founder and CEO Vin Singh discusses how the company’s end-to-end AI workflow prepares complex clinical data, identifies disease drivers and patient subgroups, and turns those insights into explainable recommendations designed to improve clinical development decisions.

Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible

When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.

Navigating FDA QMSR in 2026 

For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.

eBook: Understanding the Foundation of LNP Formulation Success

Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

On-Demand Presentation: Analytical Strategy & Challenges for ADC

Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.

America’s Next Healthcare Crisis Is Already Here - And We’re Not Ready

Bryn L. Dubin, Master’s Student at the LBJ School of Public Affairs studying health and economic policy. Dubin has federal and state legislative and policy analysis experience.

Executive Interview: Advancing Regenerative Medicine for Chronic Disease

Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.

The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve

Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.

VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development

In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.

Atossa Therapeutics: Unlocking the Platform Potential of (Z)-Endoxifen Across Oncology & Rare Disease

Dr. Steven Quay explains how (Z)-endoxifen is being positioned as both an oncology backbone therapy and a potential treatment in rare diseases with substantial unmet need.